[Antiangiogenic and antimetastatic effects of toremifene citrate].
In this study, we demonstrated that toremifene citrate (TOR) inhibited the tube formation and migration of human umbilical vein endothelial cells (HUVEC) in vitro. Moreover, TOR suppressed angiogenesis in rabbit cornea and lung metastasis of human fibrosarcoma HT-1080 cells in nude mice. The antiangiogenic activity in vitro was apparent at the concentration of 5 microM which is clinically achievable by oral administration of 120 mg/kg of TOR. These results suggest that clinical treatment with 120 mg/day of TOR might be expected to exhibit antiangiogenesis and antimetastasis effects, in addition to inhibition of estrogen-dependent tumor cell growth.
Okada
M
M
Research and Development Division, Nippon Kayaku Co., Ltd.
Ogasawara
A
A
Sekine
K
K
Seno
C
C
Nishikawa
K
K
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D016510:Corneal Neovascularization / Q000473:pathology; D004967:Estrogens / Q000502:physiology; D005354:Fibrosarcoma / Q000473:pathology*; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary*; D051379:Mice; D008819:Mice, Nude; D009362:Neoplasm Metastasis / Q000517:prevention & control; D011817:Rabbits; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology*; D017312:Toremifene / Q000494:pharmacology*
D020533:Angiogenesis Inhibitors; D004967:Estrogens; D020845:Selective Estrogen Receptor Modulators; D017312:Toremifene